{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:57Z","timestamp":1791928857408,"version":"4.3.4"},"reference-count":22,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: We investigated the role of a high-sensitive cardiac troponin T (hsTnT) increase below the upper limit of normal (ULN) in patients with breast cancer (BC). hsTnT assays accurately quantify very low plasma troponin concentrations and enable the early detection of cardiomyocyte injury before a drop in the left ventricular ejection fraction (LVEF). The increase in hsTnT below the ULN in response to chemotherapy has not previously been studied. Method: This was an open-label pilot study. Female patients with newly diagnosed BC scheduled to receive systemic cancer treatment were recruited. Blood sampling and echocardiography were performed at baseline, at 3 and 6 months of cancer treatment. hsTnT concentrations were measured using the Elecsys TnT hs assay (Roche Diagnostics). The limit of blank and 99th percentile cutoff values for the hsTnT assay were 3 and 14 ng\/L. We calculated the rise in hsTnT (\u0394hsTnT) by the difference (%) between its baseline level and during follow-up (FU) in each patient. Results: Among eligible subjects, we excluded 4 patients before the start of treatment and 17 patients during the follow-up with values for the hsTnT &gt;14 ng\/L. Finally, 60 women with a median age of 48.6 \u00b1 1.3 years were included in the study. The median baseline hsTnT concentration was 5.5 \u00b1 1.4 ng\/L. During 6 months of cancer treatment, hsTnT increased in all patients by up to 10\u2013305% from baseline, with an average of 94.2%. LV EF was normal at baseline and decreased significantly compared to the value before cancer treatment (61.9 \u00b1 3.3% vs. 56.3 \u00b1 7.0%; p &lt; 0.045). We correlated the hsTnT rise with a drop in LV EF \u2265 10% from its baseline level. Logistic regression analysis showed that \u0394 hsTnT has a good predictive value for LV dysfunction, 0.78 (p = 0.05), 95% CI (0.67\u20130.90). The increase in hsTnT &gt; 81% was determined as the optimal threshold value for detecting early biochemical cardiotoxicity. Conclusion: It was investigated that hsTnT rise within the cutoff &lt; 14 ng\/L can be used as a marker of early biochemical cardiotoxicity and is valuable for predicting LV drop in 6 months of FU. We conclude that BC patients with increased hsTnT plasma concentration &gt; 81% from the baseline value should be considered as high-risk patients for cardiotoxicity and need more precise cardiac monitoring and early preventive medical intervention strategies.<\/jats:p>","DOI":"10.3390\/cancers17142412","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T17:27:36Z","timestamp":1753118856000},"page":"2412","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Prognostic Value of High-Sensitive Troponin T Rise Within the Upper Reference Limit in Breast Cancer: A Prospective Pilot Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7973-7894","authenticated-orcid":false,"given":"Sergey","family":"Kozhukhov","sequence":"first","affiliation":[{"name":"SI NSC The M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, 03680 Kyiv, Ukraine"},{"name":"Cardio-Oncology Center, 03680 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Dovganych","sequence":"additional","affiliation":[{"name":"SI NSC The M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, 03680 Kyiv, Ukraine"},{"name":"Cardio-Oncology Center, 03680 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"ref_1","unstructured":"(2024). Cancer in Ukraine 2022\u20132023: Incidence, mortality, prevalence and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine, National Cancer Institute."},{"key":"ref_2","first-page":"17","article-title":"Cancer statistics 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4048\/jbc.2024.0085","article-title":"Breast Cancer and Therapy-Related Cardiovascular Toxicity","volume":"27","author":"Hwang","year":"2024","journal-title":"J. Breast Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Attanasio, U., Di Sarro, E., Tricarico, L., Di Lisi, D., Armentaro, G., Miceli, S., Fioretti, F., Deidda, M., Correale, M., and Novo, G. (2024). Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond. Biomolecules, 14.","DOI":"10.3390\/biom14020199"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The Role of Biomarkers in Cardio-Oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J. Cardiovasc. Trans. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e000403","DOI":"10.1161\/JAHA.113.000403","article-title":"High-sensitivity troponin assays: Evidence, indications, and reasonable use","volume":"3","author":"Sherwood","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"120000","DOI":"10.1016\/j.cca.2024.120000","article-title":"Early detection of anthracycline-induced cardiotoxicity","volume":"565","author":"Feng","year":"2025","journal-title":"Clin. Chim. Acta."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lancellotti, P., and Cosyns, B. (2016). The EACVI Echo Handbook, ESC Publications. [online ed.].","DOI":"10.1093\/med\/9780198713623.001.0001"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cca.2010.12.034","article-title":"Multicenter analytical evaluation of a high-sensitivity troponin T assay","volume":"412","author":"Saenger","year":"2011","journal-title":"Clin. Chim. Acta."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ma, W., Wei, S., Zhang, B., and Li, W. (2020). Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00434"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"m4087","DOI":"10.1136\/bmj.m4087","article-title":"Mortality due to cancer treatment delay: Systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2423(09)49001-2","article-title":"High-sensitivity troponin: A new tool for pathophysiological investigation and clinical practice","volume":"49","author":"Clerico","year":"2009","journal-title":"Adv. Clin. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.hlc.2024.02.007","article-title":"Cardiotoxicity in Oncology Guidelines: Discrepancies Do Matter","volume":"33","author":"Tan","year":"2024","journal-title":"Heart Lung Circ."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jcmg.2025.02.006","article-title":"Did You Check Diastolic Function During Cancer Treatment?: It\u2019s Not Just Systole\u2019s Show","volume":"18","author":"Barac","year":"2025","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/ehf2.13515","article-title":"High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: A single-centre cohort study","volume":"8","author":"Finke","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e014708","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations with Cardiac Dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-015-0436-2","article-title":"Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy","volume":"10","author":"Tuohinen","year":"2015","journal-title":"Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"EVIDoa2200097","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/14\/2412\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:35Z","timestamp":1760033615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/14\/2412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":22,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17142412"],"URL":"https:\/\/doi.org\/10.3390\/cancers17142412","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}